News

The European Commission (EC) has approved Sarclisa (isatuximab) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adult patients with relapsed and…
Read More...

Intravacc and EpiVax announce that they have entered into a collaboration agreement to further progress an novel vaccine against COVID-19, based on Intravacc’s proprietary Outer…
Read More...

AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the purchase of a state-of-the-art commercial manufacturing facility in…
Read More...

Baylor College of Medicine and Texas Children’s Hospital Center for Vaccine Development today announced an extension of their ongoing collaboration with Infectious Disease Research…
Read More...

-Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and immune repertoire analysis,  announces that it has identified several SARS-CoV-2-specific…
Read More...

Study in California utilizing IVIG as investigational coronavirus treatment for adults experiencing respiratory failure Following positive preliminary data, Octapharma USA is…
Read More...

Tetraphase Pharmaceuticals, Inc. announced that it has entered into a definitive merger agreement with Melinta Therapeutics, Inc. (“Melinta”), pursuant to which Melinta would acquire…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2, which showed that TREMFYA (guselkumab)…
Read More...

Pierre Fabre announced that the European Commission (EC) has approved BRAFTOVI (encorafenib) in combination with cetuximab (marketed as Erbitux) for the treatment of adult patients with…
Read More...

AgeX Therapeutics, Inc. and ImStem Biotechnology, Inc. announced their signing of a non-binding letter of intent for ImStem to obtain from AgeX a non-exclusive license to use AgeX’s…
Read More...

FSD Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of…
Read More...

PharmAbcine announced that the company entered into a license agreement with Wincal Biopharm, a wholly owned US subsidiary of PharmAbcine, so that Wincal can expand the commercial value…
Read More...

Bristol Myers Squibb announced results from True North, a pivotal Phase 3 trial evaluating oral Zeposia (ozanimod) as an induction and maintenance therapy for adult patients with…
Read More...

Predictive Oncology Inc. announced that it has completed the acquisition of the assets of Soluble Therapeutics, Inc. and BioDtech, Inc., each of which is a wholly-owned subsidiary of…
Read More...

Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, announced that it has entered into two strategic…
Read More...

AVEO Oncology announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) seeking approval for tivozanib, the Company’s next-generation…
Read More...

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most…
Read More...

AstraZeneca and MSD Inc., Kenilworth, N.J., US announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line…
Read More...

Regeneron Pharmaceuticals, Inc. and Intellia Therapeutics, Inc. announced an expansion of their existing collaboration to provide Regeneron with rights to develop products for…
Read More...

AbbVie and Jacobio Pharmaceuticals announced a global, strategic collaboration to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells. SHP2 …
Read More...